Review: Treatments for primary basal cell carcinoma compared

Review: treatments for primary basal cell carcinoma compared

(HealthDay)—For patients with primary basal cell carcinoma (BCC), estimated recurrence rates are similarly low for excision, Mohs surgery, curettage and diathermy, and external-beam radiation, according to a review and meta-analysis published online Sept. 18 in the Annals of Internal Medicine.

Aaron M. Drucker, M.D., from the Alpert Medical School of Brown University in Providence, R.I., and colleagues conducted a systematic review to examine the and safety of primary BCC treatments in adults. Eighteen interventions in nine categories were compared in 40 randomized trials and five non-randomized studies.

The researchers found that the estimated recurrence rates were similar for excision, Mohs surgery, curettage and diathermy, and external-beam radiation (3.8, 3.8, 6.9, and 3.5 percent, respectively). For cryotherapy, curettage and cryotherapy, 5-fluorouracil, imiquimod, and photodynamic therapy using methyl-aminolevulinic acid or aminolevulinic acid, the recurrence rates were higher (22.3, 19.9, 18.8, 14.1, 18.8, and 16.6 percent, respectively). Compared with excision or cryotherapy, for phototherapy using methyl-aminolevulinic acid or there was a higher proportion of patients reporting good or better cosmetic outcomes (93.8 and 95.8, respectively, versus 77.8 and 51.1 percent, respectively).

"Surgical treatments and external-beam radiation have low recurrence rates for the of low-risk BCC, but substantial uncertainty exists about their comparative effectiveness versus other treatments," the authors write. "Gaps remain regarding high-risk BCC subtypes and important outcomes, including costs."

Explore further

Curettage alone not advised for sacral giant cell tumors

More information: Abstract/Full Text
Editorial (subscription or payment may be required)
Journal information: Annals of Internal Medicine

Copyright © 2018 HealthDay. All rights reserved.

Citation: Review: Treatments for primary basal cell carcinoma compared (2018, September 18) retrieved 13 December 2019 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments